(Q38051695)

27 August 2017

title

A critical review of the use of carvedilol in ischemic heart disease (English)

1 reference

27 August 2017

1 reference

Carol Chen-Scarabelli

1

1 reference

27 August 2017

Louis Saravolatz

2

1 reference

27 August 2017

Yahya Murad

3

1 reference

27 August 2017

Wen-Shi Shieh

4

1 reference

27 August 2017

Waqas Qureshi

5

1 reference

27 August 2017

Justin Di Rezze

6

1 reference

27 August 2017

Rodeo Abrencillo

7

1 reference

27 August 2017

Tova Gardin

8

1 reference

27 August 2017

Umesh K Gidwani

9

1 reference

27 August 2017

Louis Saravolatz

10

1 reference

27 August 2017

Giuseppe Faggian

11

1 reference

27 August 2017

Tiziano M Scarabelli

12

1 reference

27 August 2017

publication date

1 December 2012

1 reference

American journal of cardiovascular drugs

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

391-401

1 reference

Role of carvedilol controlled-release in cardiovascular disease

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Protective effects of carvedilol in the myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Apoptosis in pressure overload-induced heart hypertrophy in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Free radicals and ischemic tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol (Kredex&reg;) Reduces Infarct Size in a Canine Model of Acute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Beta-blockers and coronary flow reserve: the importance of a vasodilatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Two-year clinical outcome after carvedilol-loaded stent implantation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Left ventricular remodeling after myocardial infarction: pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Predictors of late development of heart failure in stable survivors of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Evaluation of a new vasodilating beta-blocking agent, carvedilol, in exertional angina using holter monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol--clinical experience in arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11636090-000000000-00000

10.2165/11636090-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1069132424

0 references

1 reference